Genome wide studies in Multiple Myeloma identify XPO1/CRM-1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Genome wide studies in Multiple Myeloma identify XPO1/CRM-1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Learn More